1-(2,5-dimethoxyphenyl)piperazine * HCl | 1019-07-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-(2,5-dimethoxyphenyl)piperazine * HCl
• 英文别名: 1-(2,5-dimethoxyphenyl)piperazine hydrochloride；1-(2,5-dimethoxyphenyl)piperazine;hydrochloride
• CAS: 1019-07-4
• 化学式: C₁₂H₁₈N₂O₂*ClH
• 分子量: 258.748
• InChiKey: JJOFGMWQNJSNGK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.54
• 重原子数：
  17.0
• 可旋转键数：
  3.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  33.73
• 氢给体数：
  1.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  1-(2,5-dimethoxyphenyl)piperazine * HCl 在 吡啶 、 盐酸羟胺 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 2-[4-(2,5-dimethoxyphenyl)piperazin-1-yl]sulfonyl-7-(4,4-dimethylcyclohexyl)sulfonylfluoren-9-one oxime
  参考文献：
  名称：

  [EN] TRICYCLIC COMPOUNDS
  [FR] COMPOSÉS TRICYCLIQUES

  摘要：

  本文提供了包含所述化合物的药物组合物，用于治疗癌症或先天性疾病。具体的癌症和先天性疾病包括那些由YAP/TAZ介导的疾病。

  公开号：

  WO2017058716A1
• 作为产物：
  描述：

  1-溴-2,5-二甲氧基苯 在 盐酸 、 tris-(dibenzylideneacetone)dipalladium(0) 、 potassium tert-butylate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 作用下， 以 甲醇 、 甲苯 为溶剂， 反应 18.0h， 生成 1-(2,5-dimethoxyphenyl)piperazine * HCl
  参考文献：
  名称：

  [EN] TRICYCLIC COMPOUNDS
  [FR] COMPOSÉS TRICYCLIQUES

  摘要：

  本文提供了包含所述化合物的药物组合物，用于治疗癌症或先天性疾病。具体的癌症和先天性疾病包括那些由YAP/TAZ介导的疾病。

  公开号：

  WO2017058716A1

文献信息

• Design, synthesis and anticancer activity of 5-aryl-4-(4-arylpiperazine-1-carbonyl)-1,2,3-thiadiazoles as microtubule-destabilizing agents
  作者：Chao Wang、Zeyu Wang、Minghuan Gao、Yuelin Li、Yujing Zhang、Kai Bao、Yingliang Wu、Qi Guan、Daiying Zuo、Weige Zhang

  DOI：10.1016/j.bioorg.2020.104199

  日期：2021.1

  Hereby, we report our efforts on discovery and optimization of a new series of 5-aryl-4-(4-arylpiperazine-1-carbonyl)-1,2,3-thiadiazoles as new microtubule-destabilizing agents along our previous study. Guided by docking model analysis, we introduced the 1,2,3-thiadiazole moiety containing the hydrogen-bond acceptors as B-ring of XRP44X analogues. Extensive structure modifications were performed to

  在此，我们报告了我们在之前的研究中发现和优化一系列新的 5-芳基-4-(4-芳基哌嗪-1-羰基)-1,2,3-噻二唑作为新的微管不稳定剂的努力。在对接模型分析的指导下，我们引入了含有氢键受体的 1,2,3-噻二唑部分作为 XRP44X 类似物的 B 环。进行了广泛的结构修改以研究详细的结构和活性关系 (SAR)。一些化合物对三种人类癌细胞系（SGC-7901、A549 和 HeLa）表现出有效的抗增殖活性。化合物5m对三种癌细胞系表现出最高的效力。微管蛋白聚合实验表明化合物5m有效地抑制了微管蛋白聚合，免疫染色分析显示它显着破坏了微管动力学。此外，细胞周期研究表明，化合物5m在 G2/M 期显着阻止细胞周期进程。
• Design, synthesis and evaluation of antiproliferative and antitubulin activities of 5-methyl-4-aryl-3-(4-arylpiperazine-1-carbonyl)-4H-1,2,4-triazoles
  作者：Chao Wang、Yuelin Li、Tong Liu、Zeyu Wang、Yujing Zhang、Kai Bao、Yingliang Wu、Qi Guan、Daiying Zuo、Weige Zhang

  DOI：10.1016/j.bioorg.2020.103909

  日期：2020.11

  Moreover, the tubulin polymerization experiments indicated that compound 6e could inhibit the tubulin polymerization. Immunofluorescence study and cell cycle analysis clearly revealed compound 6e could disrupt intracellular microtubule organization, arrest cell cycle at the G2/M phase. In addition, molecular docking analysis demonstrated the interaction of compound 6e at the colchicine-binding site of tubulin

  设计了一系列以1,2,4-三唑为氢键受体的新型5-甲基-4-芳基-3-（4-芳基哌嗪-1-羰基）-4 H -1,2,4-三唑合成并评估了它们的抗增殖和微管蛋白聚合抑制活性。它们中的一些在体外对三种癌细胞系（包括SGC-7901，A549和HeLa）表现出中等活性。化合物6e对三种癌细胞表现出最高的效力。此外，微管蛋白聚合实验表明化合物6e可以抑制微管蛋白聚合。免疫荧光研究和细胞周期分析清楚地表明了化合物6e可能破坏细胞内微管组织，使细胞周期停滞在G2 / M期。另外，分子对接分析表明化合物6e在微管蛋白的秋水仙碱结合位点相互作用。这些初步结果表明，化合物6e是一种新型秋水仙碱结合位点抑制剂，值得进一步研究。
• HYDROQUINONE DERIVATIVES
  申请人：——

  公开号：US20010008893A1

  公开（公告）日：2001-07-19

  A hydroquinone derivative useful as an intraocular pressure lowering, anti-hypertensive and radical scavenging agent represented by the following formula 1 wherein B 1 and B 2 in formula (I) are the same or different and at any position on the benzene ring (when W is nitrogen, however, at any other position on the benzene ring) and each denotes a substituent selected from the group consisting of hydrogen, halogen, hydroxyl, lower alkoxyl and carboxyl, and the substituent CH 3 is at position 2 or 3, and W are the same or different and each denotes a nitrogen or carbon atom. R 1 , R 2 , R 3 and R 4 in formula (II) are the same or different and each denotes a substituent selected from the group consisting of hydrogen, lower alkyl and lower alkoxyl, and B 1 and B 2 are as hereinbefore defined, or a pharmacologically acceptable salt thereof.

  一种具有降低眼内压、抗高血压和自由基清除作用的有用氢醌衍生物，由以下式1表示，其中式（I）中的B1和B2相同或不同，并且在苯环上的任何位置（当W为氮时，在苯环上的任何其他位置），每个表示从氢、卤素、羟基、低级烷氧基和羧基组成的组中选择的取代基，并且取代基CH3位于位置2或3，并且W相同或不同，每个表示氮或碳原子。式（II）中的R1、R2、R3和R4相同或不同，每个表示从氢、低级烷基和低级烷氧基组成的组中选择的取代基，并且B1和B2如前所述，或其药理学上可接受的盐。
• Antivertigo agents. IV. Synthesis and antivertigo activity of 6-(.OMEGA.-(4-aryl-1-piperazinyl)alkyl)-5,6,7,8-tetrahydro-1,6-naphthyridines.
  作者：AKIRA SHIOZAWA、YUHICHIRO ICHIKAWA、CHIKARA KOMURO、MICHIO ISHIKAWA、YASUHIKO FURUTA、SHUJI KURASHIGE、HIROSHI MIYAZAKI、HIROSHI YAMANAKA、TAKAO SAKAMOTO

  DOI：10.1248/cpb.32.3981

  日期：——

  A series of novel 6-[ω-(4-aryl-1-piperazinyl) alkyl]-5, 6, 7, 8-tetrahydro-1, 6-naphthyridines was synthesized and evaluated for antivertigo activity by testing their ability to inhibit spontaneous nystagmus in cats. Structure-activity relationships are discussed. Many of the compounds having the 4-(2-alkoxyphenyl) piperazine group as the 4-arylpiperazine moiety showed more potent antivertigo activity than diphenidol. Among them, 2-2-[4-(2-ethoxyphenyl)-1-piperazinyl] ethyl}-1, 2, 3, 4, 6, 7, 8, 9-octahydrobenzo [b] [1, 6] naphthyridine (NK 422, 41) was selected as a promising antivertigo agent. NK 422 also exhibited a more potent inhibitory effect on apomorphine-induced vomiting in dogs than diphenidol.

  合成了一系列新型的6-[ω-(4-芳基-1-哌嗪基)烷基]-5, 6, 7, 8-四氢-1, 6-萘啶，并通过测试其抑制猫的自发性眼震的能力来评估其抗眩晕活性。讨论了结构-活性关系。许多具有4-(2-烷氧基芳基)哌嗪基作为4-芳基哌嗪部分的化合物显示出比二苯醇更强的抗眩晕活性。其中，2-2-[4-(2-乙氧基芳基)-1-哌嗪基]乙基}-1, 2, 3, 4, 6, 7, 8, 9-八氢苯并[b][1, 6]萘啶（NK 422, 41）被选为有前途的抗眩晕剂。NK 422在犬源性呕吐的抑制效果上也表现出比二苯醇更强的抑制作用。
• Design, synthesis and biological evaluation of 1-Aryl-5-(4-arylpiperazine-1-carbonyl)-1<i>H</i>-tetrazols as novel microtubule destabilizers
  作者：Chao Wang、Yuelin Li、Zi Liu、Zeyu Wang、Zihan Liu、Shuai Man、Yujing Zhang、Kai Bao、Yingliang Wu、Qi Guan、Daiying Zuo、Weige Zhang

  DOI：10.1080/14756366.2020.1759582

  日期：2021.1.1

  A series of 1-aryl-5-(4-arylpiperazine-1-carbonyl)-1H-tetrazols as microtubule destabilizers were designed, synthesised and evaluated for anticancer activity. Based on bioisosterism, we introduced the tetrazole moiety containing the hydrogen-bond acceptors as B-ring of XRP44X analogues. The key intermediates ethyl 1-aryl-1H-tetrazole-5-carboxylates 10 can be simply and efficiently prepared via a microwave-assisted continuous operation process. Among the compounds synthesised, compound 6-31 showed noteworthy potency against SGC-7901, A549 and HeLa cell lines. In mechanism studies, compound 6-31 inhibited tubulin polymerisation and disorganised microtubule in SGC-7901 cells by binding to tubulin. Moreover, compound 6-31 arrested SGC-7901cells in G2/M phase. This study provided a new perspective for development of antitumor agents that target tubulin.